Correction: Sustained anti-BCR–ABL activity with pH responsive imatinib mesylate loaded PCL nanoparticles in CML cells

Barbara Cortese; Stefania D'Amone; Giuseppe Gigli; Ilaria Elena Palamà

doi:10.1039/C6MD90031C

View PDF VersionPrevious ArticleNext Article

Open Access Article

This Open Access Article is licensed under a
Creative Commons Attribution 3.0 Unported Licence

DOI: 10.1039/C6MD90031C (Correction) Med. Chem. Commun., 2016, 7, 1450-1450

Correction: Sustained anti-BCR–ABL activity with pH responsive imatinib mesylate loaded PCL nanoparticles in CML cells

Barbara Cortese ^ab, Stefania D'Amone ^a, Giuseppe Gigli ^acd and Ilaria Elena Palamà *^a
^aInstitute Nanoscience CNR (NNL, CNR-NANO), via Arnesano, Lecce, Italy. E-mail: ilariaelena.palama@nano.cnr.it
^bDepartment of Physics, University Sapienza, P. le A. Moro 5, Rome, Italy
^cDept. Matematica e Fisica ‘Ennio De Giorgi’, University of Salento, via Monteroni, Lecce, Italy
^dItalian Institute of Technology (IIT) – Center for Biomolecular Nanotechnologies, via Barsanti, Arnesano, Italy

Received 16th June 2016 , Accepted 16th June 2016

First published on 24th June 2016

Abstract

Correction for ‘Sustained anti-BCR–ABL activity with pH responsive imatinib mesylate loaded PCL nanoparticles in CML cells’ by Barbara Cortese et al., Med. Chem. Commun, 2015, 6, 212–221.

The authors regret their oversight in not referencing their closely related work, previously published in Biomaterials Science, in this MedChemComm paper. For the benefit of readers the reference is provided below.^*

This MedChemComm paper presents a comprehensive study of the synthesis of the reported PCL nanoparticles, pH release of the loaded drug, the colocalization of the nanoparticles in cells, and in vitro evidence that the drug release was active against a specific molecular target, the oncoprotein BCR–ABL.

The Biomaterials Science paper reports the combination of these PCL nanoparticles with polyelectrolyte nanocomplexes for the dual delivery of two drugs, imatinib mesylate and doxorubicin.

*I. E. Palamà, B. Cortese, S. D'Amone, V. Arcadio and G. Gigli, Biomater. Sci., 2015, 3, 361–372.